RESUMEN
Color is one of the key sensory characteristics in the evaluation of the quality of mangos (Mangifera indica) especially with regard to determining the optimal level of ripeness. However, an objective color determination of entire fruits can be a challenging task. Conventional evaluation methods such as colorimetric or spectrophotometric procedures are primarily limited to a homogenous distribution of the color. Accordingly, a direct assessment of the mango quality with regard to color requires more pronounced color determination procedures. In this study, the color of the peel and the pulp of the mango cultivars "Nam Dokmai", "Mahachanok", and "Kent" was evaluated and categorized into various levels of ripeness using a charge-coupled device (CCD) camera in combination with a computer vision system and color standards. The color evaluation process is based on a transformation of the RGB (red, green, and blue) color space values into the HSI (hue, saturation, and intensity) color system and the Natural Color Standard (NCS). The results showed that for pulp color codes, 0560-Y20R and 0560-Y40R can be used as appropriate indicators for the ripeness of the cultivars "Nam Dokmai" and "Mahachanok". The peels of these two mango cultivars present two distinct colors (1050-Y40R and 1060-Y40R), which can be used to determine the fruit maturity during the post-ripening process. However, in the case of the cultivar "Kent", peel color detection was not an applicable approach for determining ripeness; thus, the determination of the pulp color with the color code 0550-Y20R gave promising results.
RESUMEN
PURPOSE: To assess the role of systemic antifungal drugs as well as the frequency of potential drug interactions and adverse drug events of commonly used antifungals in an unselected haematology/oncology patient cohort. METHODS: A prospective analysis was performed in our haematology/oncology department between October 2006 and September 2009. Data were obtained from 250 consecutive patients who received treatment and/or prophylaxis with fluconazole (n = 191), liposomal amphotericin B (n = 105), voriconazole (n = 62), caspofungin (n = 27) and/or posaconazole (n = 22). We performed detailed reviews of patient charts and laboratory values in close cooperation with treating physicians and nursing staff and participated regularly in ward and chart rounds. Potential drug interactions were assessed using the electronic database Micromedex® 1.0 (Healthcare Series). RESULTS: In terms of adverse drug events, caspofungin (56%) and voriconazole (58%) revealed a slightly more favourable safety profile than liposomal amphotericin B (66%) and posaconazole (64%). We confirmed frequent nephrotoxic effects with the use of liposomal amphotericin B (20%). Regarding potential drug interactions, 97 (66%) of 147 evaluated patients were exposed to at least 1 of 22 different potentially interacting drug combinations involving systemic antifungal agents. Cyclosporine was the most prevalent potentially interacting drug in our cohort. CONCLUSIONS: Systemic antifungal drugs are widely used in the haematology/oncology setting and exhibit numerous potential drug interactions and adverse events in cancer patients. Our results highlight the challenges related to antifungal drugs and should valuably contribute to a safe and efficient application of this increasingly important class of drugs.
Asunto(s)
Antifúngicos/uso terapéutico , Micosis/tratamiento farmacológico , Neoplasias/terapia , Adulto , Anciano , Anciano de 80 o más Años , Antifúngicos/administración & dosificación , Antifúngicos/efectos adversos , Interacciones Farmacológicas , Femenino , Hematología , Humanos , Masculino , Oncología Médica , Persona de Mediana Edad , Micosis/etiología , Micosis/prevención & control , Neoplasias/complicaciones , Estudios ProspectivosRESUMEN
Parallel administration of the proton pump inhibitor (PPI) esomeprazole has been shown to decrease oral bioavailability of posaconazole in healthy volunteers. We prospectively analyzed serum samples (n = 59) obtained from hematology patients (n = 27) under posaconazole prophylaxis. Patients treated concomitantly with pantoprazole had significantly lower posaconazole levels than patients without PPI treatment (median levels of 630 microg/liter versus 1,125 microg/liter, respectively). These results suggest that drug monitoring is relevant when posaconazole and pantoprazole are administered concomitantly.
Asunto(s)
Antifúngicos/uso terapéutico , Neoplasias Hematológicas/microbiología , Triazoles/uso terapéutico , Adulto , Anciano , Cromatografía Líquida de Alta Presión , Femenino , Humanos , Masculino , Persona de Mediana Edad , Micosis/tratamiento farmacológico , Estudios ProspectivosRESUMEN
Posaconazole is a new broad-spectrum antifungal agent that is currently only available as an oral suspension and shows high intra- and inter-individual differences in oral bioavailibility. Pre-existing methods for the determination of the substance involve the use of internal standards or require a quite complicated and time-consuming sample pre-treatment. Our HPLC method is fast and fully-automated and there is no need for any manual sample pre-treatment. On-line transfer of posaconazole from the extraction column was followed by chromatographic separation on a C18 column and fluorescence detection (lambda(ex): 261 nm, lambda(em): 357 nm). Retention time of posaconazole was about 11.7 min, the lower limit of quantification was found to be 0.1 mg/l. A linear calibration curve was obtained over the concentration range of 0.1-5 mg/l using a 50 microl sample (r(2)=0.999). The relative standard deviations of intra-day variations ranged from 2.3% to 9.4%, intra-day accuracy from 88.8% to 114.8%.